COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREVENTION INTERVENTIONS IN CHILDREN: A MODEL COMPARISON STUDY

被引：0
|
作者：
Li, X. X. [1 ]
Hodgson, D. [2 ]
Flaig, J. [3 ]
Kieffer, A. [4 ]
Herring, W. [5 ]
Beyhaghi, H. [6 ]
Williem, L. [1 ]
Jit, M. [2 ]
Bilcke, J. [1 ]
Beutels, P. [1 ]
机构：
[1] Univ Antwerp, Antwerp, Van, Belgium
[2] London Sch Hyg & Trop Med, London, England
[3] Epidemiol & Modeling Infect Dis EPIMOD, Lyon, France
[4] Sanofi, Lyon, France
[5] RTI Hlth Solut, Res Triangle Pk, NC USA
[6] Novavax Inc, Durham, NC USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE622
引用
收藏
页码：S178 / S178
页数：1
相关论文
共 50 条
  • [11] The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
    Blanken, Maarten
    Bont, Louis
    Rovers, Maroeska
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2011, 7 (03) : 203 - 212
  • [12] COST-EFFECTIVENESS OF NIRSEVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) AMONG US INFANTS EXPERIENCING THEIR FIRST RSV SEASON
    Beuvelet, M.
    Chung-Delgado, K.
    Kieffer, A.
    VALUE IN HEALTH, 2021, 24 : S110 - S110
  • [13] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Reeve, Carole A.
    Whitehall, John S.
    Buettner, Petra G.
    Norton, Robert
    Reeve, David M.
    Francis, Fleur
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
  • [14] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Mahadevia, Parthiv J.
    Malinoski, Frank J.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 519 - 520
  • [15] A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Hussman, Julia M.
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 553 - 567
  • [16] BURDEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND POTENTIAL IMPACT OF PROPHYLAXIS IN INFANTS IN SWEDEN: A COST-EFFECTIVENESS ANALYSIS
    Neovius, K.
    Buesch, K.
    Neovius, M.
    ACTA PAEDIATRICA, 2010, 99 : 96 - 97
  • [17] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE
    Kang, H. Y.
    Kim, H. S.
    Choi, J. Y.
    Kim, Y. H.
    VALUE IN HEALTH, 2009, 12 (07) : A424 - A424
  • [18] Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Solakidi, Argyro
    Markatis, Eleftherios
    Detsis, Marios
    Mendes, Diana
    Barmpouni, Myrto
    VACCINES, 2024, 12 (11)
  • [19] Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina (vol 42, 126234, 2024)
    Guinazu, Gonzalo
    Dvorkin, Julia
    Mahmud, Sarwat
    Baral, Ranju
    Pecenka, Clint
    Libster, Romina
    Clark, Andrew
    Caballero, Mauricio T.
    VACCINE, 2025, 44
  • [20] Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
    Averin, Ahuva
    Huebbe, Bennet
    Atwood, Mark
    Bayer, Lea J.
    Lade, Caroline
    von Eiff, Christof
    Sato, Reiko
    EXPERT REVIEW OF VACCINES, 2025, 24 (01) : 1 - 10
12345